Analytical Data
-
基因名
AngII
- Application
-
别名
AngII；Nalp6；Navr；Pypaf5；NACHT. LRR and PYD domains-containing Protein 6
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P01019
-
表达区间
44-427aa
-
氨基酸序列
VIHNESTCEQLAKANAGKPKDPTFIPAPIQAKTSPVDEKALQDQLVLVAAKLDTEDKLRAAMVGMLANFLGFRIYGMHSELWGVVHGATVLSPTAVFGTLASLYLGALDHTADRLQAILGVPWKDKNCTSRLDAHKVLSALQAVQGLLVAQGRADSQAQLLLSTVVGVFTAPGLHLKQPFVQGLALYTPVVLPRSLDFTELDVAAEKIDRFMQAVTGWKTGCSLMGASVDSTLAFNTYVHFQGKMKGFSLLAEPQEFWVDNSTSVSVPMLSGMGTFQHWSDIQDNFSVTQVPFTESACLLLIQPHYASDLDKVEGLTFQQNSLNWMKKLSPRTIHLTMPQLVLQGSYDLQDLLAQAELPAILHTELNLQKLSNDRIRVGEVLNS
-
分子量
57.9kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Recombinant Human LOXHD1 Protein，GST
Cat：PA2000-9043
Recombinant Human NDUFB4 Protein，His
Cat：PA1000-2119
Protein Description
Angiotensin II (AngII) is a pivotal peptide in the renin-angiotensin system, playing a crucial role in regulating blood pressure, fluid balance, and electrolyte homeostasis. It is formed through the enzymatic activity of angiotensin-converting enzyme (ACE) on angiotensin I, and its binding to angiotensin receptors triggers various physiological responses, including vasoconstriction and aldosterone secretion. Given its significant involvement in cardiovascular diseases, including hypertension and heart failure, extensive research has focused on the therapeutic potential of AngII and its analogs. Recent advances in recombinant protein technology have enabled the production of AngII variants with modified properties, allowing for the exploration of their effects on the cardiovascular system and potential therapeutic uses. Understanding the structure-function relationship of AngII, along with its interactions with receptor subtypes, provides insights into drug design and the development of new treatments targeting cardiovascular and metabolic disorders. The study of AngII recombinant proteins thus represents a promising avenue for innovative therapeutic strategies aimed at mitigating the adverse effects of dysregulated AngII signaling in various pathological conditions. This research not only enhances our understanding of the molecular mechanisms underlying AngII function but also paves the way for the development of novel interventions for related diseases.
